top of page
Newsroom Latest News
Newsroom: In the News
IGX12 Feature in the REPROFACTS 2025 Report
IGX12 featured in the REPROFACTS 2025 report, an independent, curated industry publication highlighting key scientific advances in reproductive medicine and endocrinology.
​
The report includes expert commentary on Igyxos’ single ascending dose (SAD) study, recognising IGX12 as a first-in-class therapeutic concept in reproductive endocrinology and highlighting its novel mechanism of action, favourable tolerability profile, and long half-life, which may support less frequent dosing in fertility treatment.
​
bottom of page